image credit: Freepik

Practice Change Needed for Gastroesophageal Cancer?

April 1, 2021

Treatment with pembrolizumab (Keytruda) improved survival for patients with microsatellite instability-high (MSI-H) gastric or gastroesophageal junction (GEJ) cancer, irrespective of the number of prior therapies, a retrospective analysis of three clinical trials suggested.

The median overall survival (OS) with pembrolizumab-containing therapy was not reached in the MSI-H subgroup in any of the trials, which involved previously treated and untreated patients. Median progression-free survival (PFS) was not reached in a noncomparative trial and exceeded median PFS with chemotherapy in the two randomized trials.

Read More on MedPageToday